Unrelated donor marrow transplantation is associated with an increased incidence of graft-versus-host disease (GVHD) compared with sibling donor transplants. Forty-one patients undergoing unrelated donor transplants were treated with a GVHD prophylaxis regimen that consisted of continuous infusion cyclosporine from day −1 to 100 days post transplant along with nifedipine, glucocorticoids and short-course methotrexate. The regimen was well-tolerated in this cohort with mostly high risk disease. Fifty-one percent of patients developed acute GVHD, which was grade III-IV in 22% of patients. Six of 22 patients at risk for chronic GVHD developed extensive chronic GVHD, five of whom were adults. In patients Ͻ18 years of age, there was a Ͼ40% chance of 2 year disease-free survival. Use of continuous infusion cyclosporine with nifedipine as an immunosuppressant and protectant against cyclosporine-induced toxicities in unrelated donor transplants is well-tolerated, and results in acute GVHD incidence favorable to that reported with bolus cyclosporine.
The largest experience with allogeneic marrow transplantation has involved the use of sibling donors genotypically identical to the recipient at the HLA-A, B, and DR histocompatibility loci. Only about 30% of allogeneic transplantation candidates have a matched sibling donor, a situation which has led to the utilization of unrelated donors or of partially histocompatible relatives. Both of these transplant types are associated with an increased risk of graft-versushost disease (GVHD), and several types of interventions have been employed to minimize the increased complication rates seen with these types of transplants. 1 The use of T cell depletion of the donor graft has decreased the incidence of GVHD, but overall benefit of this decrease has often been offset by an increase in graft failure and/or leukemic relapse.
Since June 1992, our institution has used a GVHD prophylaxis regimen for unrelated donor transplant recipients consisting of continuous infusion cyclosporine until day 100 post transplant with the concurrent use of nifedipine. In addition, patients receive a short course of low-dose methotrexate as well as glucocorticoids from day +7 to day +40. This regimen was designed to maximize peri-and post-transplantation immunosuppression of the marrow recipient without the use of in vitro T cell depletion. Continuous infusion cyclosporine was chosen to optimize sustained cyclosporine levels and minimize attendant renal or hepatotoxicity associated with peak levels. In HLA-identical adult allogeneic transplants, use of continuous intravenous cyclosporine A infusion has been reported at 2.5 mg/kg/day until day +20 post-marrow infusion. 4 No patient had a serum creatinine Ͻ2 mg/dl while on this infusion. Tremor and hypertension responsive to nifedipine were the only side-effects noted. 4 Since the nephrotoxicity and hypertension associated with cyclosporine use can often be modified by concurrent use of calcium channel antagonists such as nifedipine, 5, 6 this agent was given concurrently with continuous infusion cyclosporine. In addition to their possible beneficial effects in prevention of cyclosporinemediated side-effects, calcium channel blockers can also produce immunosuppression independently of cyclosporine. [7] [8] [9] We report here the results of 41 consecutive unrelated donor transplants performed with this GVHD prophylaxis regimen utilizing a consistent conditioning regimen between June 1992 and October 1996.
Materials and methods

Patients
The study population consisted of 41 consecutive patients transplanted with marrow from unrelated donors at the University of Rochester between 1992 and October 1996. Outcomes were assessed as of October 1997. All patients gave written informed consent for the transplant procedure in accordance with policies of the University of Rochester Research Subjects Review Board. Transplants were performed as part of treatment for both malignant and non-malignant conditions as shown in Table 1 . All patients had ECOG performance status of 0-2, and all had acceptable baseline function of renal (CrCl Ͼ 50 ml/min or serum cre- atinine Ͻ2 mg/dl), hepatic, pulmonary, and cardiac (LVEF Ͼ 50%) function. All patients tested negative for HIV antibody. No patient had a 6/6 or a 5/6 family member available for marrow donation. Eight of the 41 patients had had prior autologous transplants performed either at our institution or elsewhere.
Donor bone marrow
Unrelated donors were selected to meet all requirements of the National Marrow Donor Program. In situations where there were two or more acceptable donors, donors of like sex who were CMV titer negative were selected. Thirtyseven donors were provided by the National Marrow Donor Program, and four were provided by the Anthony Nolan Registry. Typing for HLA-A and B antigens was performed according to the standard National Institutes of Health twostage microcytotoxicity assay. HLA-D region compatibility was defined as identity for DRB1 alleles determined by DNA hybridization with sequence-specific oligonucleotide probes. Such DRB1 typing was begun in 1994. 10 The transplanted marrow was infused without manipulation except in instances of ABO incompatibility. Ex vivo T cell depletion was not performed.
Conditioning regimen
The preparative regimen consisted of fractionated total body irradiation (FTBI) to a final dose of 14 Gy administered as twice/day fractions for 4 days, on days −8 (one fraction), −7, −6, −5 and −4 (one fraction). Etoposide was given as a single dose of 30 mg/kg on day −4. Cyclophosphamide was administered on days −3 and Ϫ2 at a dosage of 60 mg/kg ideal body weight. Mesna was administered concurrently with the cyclophosphamide as a continuous infusion and was continued until 24 h after cyclophosphamide was completed. Methylprednisolone, 1 g/m 2 was given every 12 h for six doses on days −3, −2 and −1 to further immunosuppress the recipient.
GVHD prophylaxis
Cyclosporine: Cyclosporine was started on day −1 and administered by continuous infusion intravenously until day +100 post-transplantation either by I-med or by portable infusion pump upon discharge. Non-PVC (polyvinylchloride) tubing was utilized. The initial dosage of cyclosporine was 3.0 mg/kg/day, and the dose was adjusted to maintain a whole blood steady-state level of 300-450 ng/ml on days 1 to 50 and 250-350 ng/ml on days 50 to 100. Levels were checked at least three times/week during the acute transplant phase and at least twice/week after discharge to day +100. The infusion was held for a serum creatinine Ͼ2.5 mg/dl (or a three-fold increase above baseline) until the creatinine returned to Ͻ2.0. For levels above the target range, the infusion was held for 4 h and restarted at a 10% decreased dosage. For levels below targets, the dosage was increased by 10%. Levels were rechecked 24 h after dosage adjustment. After day 100, unless GVHD was active, cyclosporine was given orally, and tapering was instituted depending upon GVHD status.
Methotrexate:
Methotrexate was given at a dosage of 10 mg/m 2 on day +1 and 7.5 mg/m 2 on days +3, +6 and +11. Doses were held or reduced based upon serum bilirubin elevation.
Steroids: On day +7, methylprednisolone was given intravenously as a single daily dose of 1.5 mg/kg until day +25, and thereafter, prednisone 1 mg/kg/day was given until day +40 after which time doses were tapered by 10% per week in cases where treatment of GVHD was not required.
Calcium channel blockers:
Nifedipine was administered at a dosage of 10 mg three times a day orally or sublingually from day −4 until discontinuation of cyclosporine. After discharge, long-acting oral preparations of nifedipine were often substituted, eg Procardia XL, 30 mg/day (Pfizer, New York, NY, USA).
Infection prophylaxis
Patients received prophylactic amphotericin B from day 0 to day +40 at a dose of 5 mg/day (0.1 mg/kg/day for patients Ͻ 50 kg). When patients were taking oral medi-cations, this was replaced by fluconazole dosed according to patient weight.
Other supportive care
All patients had placement of a triple lumen or two double lumen indwelling central catheter(s). Patients who were seropositive for herpes simplex virus received acyclovir 250 mg/m 2 every 8 h until engraftment. Acyclovir was administered at 500 mg/m 2 every 8 h if patient or donor were CMV seropositive. These patients also received IVIG every 2 weeks at a dosage of 0.5 g/kg. CMV was treated pre-emptively based upon surveillance culture results. Beginning in 1993, for patient/donor pairs where either or both were seropositive for CMV, prophylactic ganclyclovir was utilized after the ANC rose to у1000 l post transplant. During granulocytopenic periods, broad-spectrum antibacterial coverage was used empirically with addition of therapeutic doses of amphotericin B after 48-72 h of fever not initially responsive to antibacterial therapy.
Treatment of GVHD
Patients who developed acute GVHD were first treated with methylprednisolone 1-2 mg/kg per day for 3-7 days with appropriate taper thereafter. For those not responding to an increase in steroid dosage further treatment was at the discretion of the attending physician.
Data analysis
Engraftment was defined as the first of 3 consecutive days where the neutrophil count exceeded 0.5 × 10 9 /l or the platelet count exceeded 20 × 10 9 /l in the absence of platelet transfusion. Acute and chronic GVHD were staged and graded based upon previously published criteria.
11,12 Survival was estimated utilizing the Kaplan-Meier estimate of probabilities. Tests of significance employed log-rank testing. These were performed with Statisca Software (Statsoft, Tulsa, OK, USA).
Results
Characteristics of transplanted patients
Forty-one patients were transplanted with the regimen described above. The preparative regimen was adhered to with the exception of one patient who had a creatinine elevation during administration of total body irradiation in which case the dose of VP-16 was decreased. This deterioration of renal function occurred before cyclosporine was begun, and this was the only patient in this study requiring dialysis. Characteristics of the 41 patients are shown in Table 1 . For patients transplanted with malignancy, all except four had high risk disease (eg AML beyond first remission or for CML, accelerated or blast phase). In 27 of the 41 cases, the donor-recipient pairs were matched at 6/6 loci. In 14, a one locus A or B mismatch was present. No patients were serologically mismatched at the D locus. Thirteen donor-recipient pairs were sex mismatched.
Engraftment
In the 37 patients evaluable for engraftment, the mean time to ANC Ͼ 0.1 × 10 9 /l was 18.3 ± 0.97 (s.e.) days, to ANC Ͼ 0.5 × 10 9 /l was 20.7 ± 0.97 (s.e.) days, and to a platelet count of 20 × 10 9 /l or greater, 27.45 ± 2.26 (s.e.) days. Five of the 37 patients alive past 28 days never reached a platelet count of 20 × 10 9 /l, usually in the setting of acute GVHD. Engraftment data was not available for one patient. Patients did not routinely receive hematopoietic growth factors post-marrow infusion. Figure 1 shows the baseline, mean and maximum creatinine values for the entire patient population during the 100 days of continuous cyclosporine infusion. Mean creatinine during the 100 days was 0.98 ± 0.08 mg/dl (s.e.). Mean maximum creatinine was 1.9 ± 0.2 mg/dl (s.e.), indicating that in most patients on this regimen, the cyclosporine infusion was not discontinued. Only two patients, both of whom died of regimen-related toxicity at day +5 and day +7 did not attain target cyclosporine levels. No patient developed seizures during the 100 days of continuous infusion cyclosporine therapy except for one child who had mental status changes and an MRI that was consistent with CNS toxicity due to cyclosporine. Only five patients required antihypertensive medication in addition to the nifedipine, and all of these patients were Ͻ18 years old. ACE inhibitors and beta blockers were usually the first antihypertensives utilized. Beta blockers were used cautiously in patients who had received prior anthracycline therapy. No other significant toxicities were noted. In only one adult patient was tremor disruptive to normal activities. Median cyclosporine level during the 100 days of continuous infusion was 360 ng/dl (see Figure 2) . Mean maximum bilirubin level was 14.3 mg/dl with a median maximum of 6.3 mg/dl (range 0.3-78). In most cases, bilirubin elevations were explained by hepatic acute GVHD and were not Figure 2 Cyclosporine levels during the 100 days of continuous cyclosporine infusion. Shown are the median, minimum, maximum, and lower and upper quartile levels for serum cyclosporine levels (ng/ml). Table 2 GVHD incidence (n = 37) attributable to use of cyclosporine. No patient developed post-transplant hemolytic uremic syndrome.
Toxicity of the GVHD prophylaxis regimen
Graft-versus-host disease
Of the 37 patients who survived to time of engraftment, 19 (51%) developed acute GVHD. Grades of acute GVHD in these 19 patients are shown in Table 2 . Of the 22 patients surviving past day +100, two had progressive severe acute GVHD, nine developed no clinically detectable chronic GVHD, five developed limited chronic GVHD, and six (five adults) developed extensive chronic GVHD. All these patients had biopsy-proven chronic GVHD, but surveillance biopsies were not performed.
Survival and causes of death
Eleven patients are alive 424-1699 days post transplant with a median follow-up in these patients of 894 days. Causes of death in the remaining 30 patients are shown in Table 3 . Five patients succumbed to grade IV acute GVHD. Relapsed disease accounted for eight deaths, with relapse occurring from 30 to 208 days post transplantation. Sixteen regimen-related toxicities and infections accounted for the remaining deaths with the exception of one patient who developed a malignant fibrous histiocytoma 1038 days from transplant. This patient died 1414 days post-transplantation despite excision, radiation and chemotherapy treatments. Figure 3a and b show the Kaplan-Meier estimate of survival for the entire population from the time of transplant (Figure 3a ) and for the adult vs pediatric patient groups (Figure 3b ). Survival with this preparative and GVHD prophylaxis regimen was significantly better in patients Ͻ18 years of age (P = 0.01).
Status of surviving patients
Two surviving adult patients have extensive chronic GVHD. Three of the nine surviving children have limited chronic GVHD confined to skin (two) or mucosal surfaces with chronic sinusitis (one), with the remaining six having no clinically significant GVHD.
Discussion
This report of 41 consecutive unrelated donor transplants performed at a single institution with a uniform preparative and GVHD prophylaxis regimen, demonstrated the feasibility of using cyclosporine as a continuous infusion until day +100. When combined with nifedipine treatment, minimal renal toxicity was noted despite the maintenance of high cyclosporine levels (median value of 360 ng/dl) in all specimens from all patients to day +100. Seventy-five percent of all measured levels were 295 ng/dl or above during this 100 day period. Minimal hypertension was noted with concurrent nifedipine, and other toxicities including neurotoxicities, were rare. Patients, family members and home care providers had no significant difficulties in maintaining the infusion pumps after discharge to home or local lodgings.
With this GVHD prophylaxis regimen, 49% of patients living to time of engraftment experienced acute GVHD. This was of grade III to grade IV severity in eight (22%) of these patients, and all patients who developed grade III/IV GVHD on this regimen eventually died from complications of the acute GVHD or from progressive chronic GVHD (61 to 316 days post transplant, median 99 days). Patients developing severe acute GVHD were treated in a variety of ways, usually with higher doses of steroids and with antithymocyte globulin. Of the 23 patients who survived 100 or more days after transplant, two had severe extensive chronic GVHD which progressed from severe acute GVHD; six developed extensive chronic GVHD without previous severe acute GVHD, five of whom were adults; five developed limited chronic GVHD, and eight developed no clinically detectable chronic GVHD. In this population, GVHD diagnosis was biopsy-confirmed, but routine biopsies were not performed in the absence of signs or symptoms of chronic GVHD.
Utilization of the continuous infusion cyclosporine regimen in conjunction with short-course methotrexate and steroids resulted in an incidence of acute GVHD which compares favorably to that usually reported after unrelated donor marrow transplantation. Grades II to IV acute GVHD occur in 59% to 79% of patients and grades III to IV acute GVHD in 36 to 47% with most reported series having used standard cyclosporine and short-course methotrexate for prophylaxis with/without T cell depletion. 1, [13] [14] [15] [16] Using a regimen of standard cyclosporine, methotrexate and prednisone, Nademanee et al 17 reported a 38% overall incidence of grade I-IV acute GVHD. In a series of patients undergoing unrelated donor marrow transplants where cyclosporine, methotrexate and anti-CD5-ricin A chain immunotoxin were utilized for GVHD prophylaxis, the incidence of acute GVHD of grade II or higher was 58%, and 24% had grade III-IV acute GVHD. 18 Recently, series of unrelated donor transplants have been reported using FK506 in combination with methotrexate for prophylaxis of GVHD. Nash et al 19 reported a 42% incidence of acute GVHD and a 48% probability of developing GVHD within 2 years of transplant. There was a 37% cumulative incidence of transplant-related mortality during the first 100 days, comparable to the 100 day mortality rate seen in this series of high-risk transplant patients.
Przepiorka et al
20 also reported on the use of tacrolimus and mini-dose methotrexate for prevention of acute GVHD after matched unrelated donor transplantation. In that series of 30 adults, the incidence of grades II-IV GVHD was 34% and of grades III-IV, 17%. In this series using continuous infusion cyclosporine with nifedipine and short-course methotrexate and steroids, total incidence of grades II-IV GVHD was 45%, and 22% had grades III-IV acute GVHD with minimal renal toxicity.
As in other reported series of unrelated donor transplants, regimen-related toxicity was a major cause of mortality, especially in this group of patients transplanted with high risk disease states and particularly in adults. [21] [22] [23] This may be a reflection of the intensity of the conditioning regimen, but separating the effects of regimen intensity from underlying disease and impact of previous treatments is not possible in this small series. It is interesting to note that no patients Ͻ18 years old died of regimen-related toxicity post transplant with the only two children dying prior to day 100 of infectious (CMV) complications. The disease-free survival of 60% at 2 years post transplant in children transplanted with this regimen compares favorably to that reported in other series. 24, 25 Four of six adults who had an unrelated transplant after an autologous transplant died before day +100. With this intensive conditioning regimen, and absence of in vitro T cell depletion, no late engraftment failure occurred. While deaths due to infection occurred, no significant numbers of opportunistic fungal infections occurred in the setting of continuous infusion cyclosporine and steroids. Two children died of CMV pneumonitis despite prophylactic and preemptive treatment attempts. One adult died of a malignant solid tumor post transplant. 26 In this series largely of high-risk patients, the overall disease relapse rate was 27%. To what extent optimization of cyclosporine levels and concurrent use of nifedipine with its reported immunomodulating effects might increase risk for relapse after unrelated donor transplants is unknown. Most relapses did occur in patients who had no or mild GVHD. One of the advantages of unrelated donor transplants, especially in good risk disease categories such as CML or AML in first remission is the low relapse rate presumably contributed to by a higher activity of the graftversus-leukemia phenomenon in cases where T cell depletion is not used. Larger controlled studies would be required to enable understanding of the role of GVHD prophylaxis regimens in disease relapse in this patient group. At this juncture, the GVHD regimen reported here is administered without significant toxicity, and results in GVHD incidences that compare favorably with those previously reported in non-T cell-depleted unrelated donor transplants and appear comparable to regimens that employ FK506 in this setting.
